Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30543480 | 0.98 | GRB2 (0.46) | GRB2NTSR1NTSR2F2OPRD1 | |
| SCHEMBL31197912 | 0.91 | GRB2 (0.44) | GRB2NTSR1NTSR2OPRD1OPRM1 | |
| SCHEMBL30543476 | 0.91 | GRB2 (0.44) | GRB2NTSR1NTSR2F2OPRD1 | |
| SCHEMBL38651991 | 0.91 | APLNR (0.43) | GRB2NTSR1NTSR2F2OPRD1 | |
| SCHEMBL38651853 | 0.91 | GRB2 (0.48) | GRB2NTSR1NTSR2F2SORT1 | |
| SCHEMBL30423238 | 0.91 | GRB2 (0.46) | GRB2OPRD1OPRM1BDKRB2CXCR4 | |
| SCHEMBL29468766 | 0.91 | GRB2 (0.42) | GRB2OPRD1OPRM1BDKRB2 | |
| SCHEMBL30414346 | 0.90 | GRB2 (0.42) | GRB2OPRD1OPRM1BDKRB2 | |
| SCHEMBL31337813 | 0.89 | GRB2 (0.44) | GRB2NTSR1OPRD1OPRM1BDKRB2 | |
| SCHEMBL29468784 | 0.89 | REN (0.46) | GRB2NTSR1NTSR2F2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424063-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL IND LTD (IN) | 2024-12-26 | — | — | US | disclosed |
| EP-4204440-A1 | GLP-1/GIP DUAL AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2023-07-05 | — | — | EP | disclosed |
| EP-4146248-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022079639-A1 | GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424063-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | GLP1R, GIPR, GPR119 | GRB2 524/4885NTSR1 78/4885NTSR2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.